We are live on ! Find out more
ERNA icon

Eterna Therapeutics

34 hedge funds and large institutions have $5.66M invested in Eterna Therapeutics in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,700% more call options, than puts

Call options by funds: $96K | Put options by funds: $2K

0% less ownership

Funds ownership: 0%0% (-0%)

27% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 11

31% less funds holding

Funds holding: 4934 (-15)

59% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 22

85% less capital invested

Capital invested by funds: $38.4M → $5.66M (-$32.8M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
34
Holders Change
-15
Holders Change %
-30.61%
% of All Funds
0.57%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
9
Increased
8
Reduced
11
Closed
22
Calls
$96K
Puts
$2K
Net Calls
+$94K
Net Calls Change
-$156K

ERNA Hedge Fund Activity: Q2 2022 in Review

34 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q2 2022, worth a combined $5.66M — down 85% from $38.4M a quarter earlier.

Sellers outnumbered buyers: 22 funds closed out of ERNA and 9 opened new positions — a net loss of 13 holders — while 11 trimmed existing stakes and 8 added.

The largest buyer was Renaissance Technologies, adding an estimated $603K. The largest seller was BlackRock, cutting an estimated $1.13M.

  • 34 institutional investors held Eterna Therapeutics (ERNA) as of Q2 2022, down from 49 in Q1 2022.
  • Funds reported $5.66M of Eterna Therapeutics stock for Q2 2022, down 85% quarter-over-quarter.
  • 9 funds opened new Eterna Therapeutics positions in Q2 2022 and 22 closed out, a net change of -13 holders.
  • The largest Eterna Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $603K added.
  • The largest Eterna Therapeutics seller in Q2 2022 was BlackRock, an estimated $1.13M sold.

Based on aggregated 13F filings for Q2 2022.